The company was founded in 1998 and is based in Hennigsdorf, Germany. Europroteome AG develops diagnostic, immunological, and prognostic tools. The Company further announced that it has granted an aggregate of 25,000 stock options at an exercise price of $2.20 per common share to certain officers and directors of the company. Europroteome AG develops diagnostic, immunological, and prognostic tools as well as patient-specific therapies for human epithelial cancers. Summary People Technology Signals & News. This expansion should support a broad array of potential product offerings and to create numerous additional opportunities for the company. Odermatt Käserei AG finden Sie unter den folgenden Suchbegriffen Käserei, Molkerei, Körperpflege, Käse gate24. The company expects to capitalize on the acquisition by using the cancer markers previously validated by Europroteome in conjunction with the BESTPlatform to accelerate Miraculins' expansion into additional cancer areas. moneyhouse.ch moneyhouse.ch Odermatt Käserei AG, Dallenwil - Handelsregister- und. With this acquisition, Miraculins expands its growing technological capabilities in the development of diagnostic tools in cancers for which there are presently insufficient or clinically inadequate diagnostic methods. "We believe this transaction has created significant value for our shareholders," he added.Įuroproteome's technology is a strong complement to Miraculins research expertise. EUROPROTEOME AG announced that it has entered into a collaboration for evaluation of approaches for molecular profiling of tissue specimens from cancer patients with ALTANA Pharma AG. "This acquisition considerably advances our product development efforts by integrating the valuable IP developed by a company that spent more than EUR15 million on research and development," stated Jim Charlton, president of Miraculins. Miraculins purchased all rights to the patents and has no further milestone or royalty commitments related to the patents. Awema AG, bisher in Pfäffikon, CHE-106.961.499, Aktiengesellschaft (SHAB Nr. Canadian Intellectual Property Office (CIPO) Trademarks filed by EUROPROTEOME AG, at D-16761 Hennigsdorf, GERMANY : Trademark Elite. WINNIPEG, MANITOBA - Miraculins Inc., a biotechnology company engaged in the discovery and development of products for select cancers, announced on Thursday that it has acquired intellectual property (IP) assets of Europroteome AG, a former developer of products for the diagnostic, prognostic, and patient specific therapy of human cancers.Īccording to a press release by the company, the IP portfolio acquired by Miraculins includes 14 patents and numerous discoveries, related to the diagnosis and treatment of several cancers, that utilized the human sample collection of Europroteome, which contained samples from greater than 4,000 patients. This copy is for your personal, non-commercial use.
0 kommentar(er)
